[1] University of Aberdeen,Academic Urology Unit
[2] Erasmus MC,Guidelines Office
[3] European Association of Urology,Translational Oncology and Urology Research
[4] Astellas,Department of Translational Medicine
[5] Imperial College London,Department of Urology and Division of Experimental Oncology, Urological Research Institute
[6] IQVIA,undefined
[7] Bayer AG,undefined
[8] Association EISBM,undefined
[9] King’s College London,undefined
[10] European Alliance for Personalised Medicine (EAPM),undefined
[11] Lund University,undefined
[12] Vita-Salute San Raffaele University,undefined
[13] IRCCS San Raffaele Scientific Institute,undefined
[14] The Hyve,undefined
[15] Sanofi,undefined
[16] Pinsent Masons,undefined
[17] Tampere University (TAU),undefined
[18] SAS,undefined
[19] Weizmann Institute,undefined
[20] The Swedish Institute for Health Economics (IHE),undefined
[21] Fraunhofer IZI,undefined
[22] ttopstart,undefined
[23] Orion Corporation,undefined
[24] The eCancer Global Foundation (eGF-eCancer),undefined
[25] European Cancer Patient Coalition (ECPC),undefined
[26] Janssen Pharmaceutica NV,undefined
[27] Goeteborgs Universitet (UGOT),undefined
[28] Technische Universität Dresden (TUD),undefined
[29] Radbound University Medical Center,undefined
[30] European Organisation for Research and Treatment of Cancer (EORTC),undefined
[31] Universitätsklinikum Hamburg-Eppendorf (UKE),undefined